IN8bio up after H.C. Wainwright initiates with 'buy'
Brief: IN8bio Announces Closing Of $10.25 Million Underwritten Public Offering Of Common Stock
Brief: In8bio Reports Second Quarter 2022 Financial Results And Provides Corporate Update
Brief: In8bio Prices Public Offering Of 5.39 Mln Shares at $1.90/Shr
Brief: IN8bio Inc - Preliminary Estimate That Net Loss For Three Ended June 30 Is Expected To Be About $7.2 Mln And $13.3 Mln Respectively
Brief: In8bio Observes Durable Morphologic Complete Responses In Ongoing Phase 1 Clinical Trial Of INB-100
Brief: In8bio, Inc. - Announced Issuance Of Additional European Patent Covering Composition Of Matter For Co's Drug Resistant Immunotherapy (Dri) Platform
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:01 PM
Brief: IN8bio Announces Positive Updates From GBM Treatment Phase 1 Trial Presented At ASCO 2022
Brief: In8bio Announces Data Emerging From Its Recently Unveiled Gamma-Delta T Cell "Off-The-Shelf" Induced Pluripotent Stem Cell Platform
Brief: In8bio Reports Q1 Loss Per Share Of $0.33
Brief: IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments
Brief: In8bio Presents Clinical Update From Ongoing Phase 1 Trial Of Inb-100 In Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Brief: IN8bio Reports Q4 And Full-Year 2021 Financial Results
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:54 AM
Brief: In8bio Announces Updates From Phase 1 Trial Of Genetically Modified Gamma-Delta T Cell Therapy
Brief: IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Brief: In8bio Posts Q3 Loss Per Share Of $0.25
Brief: In8bio’S Announces Publication Of Preclinical Results In Mouse Models Of Glioblastoma Multiforme